LOSTOCK PHARMACHEM LIMITED
Company number 13111184 · Monitor this company
This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.
LOSTOCK PHARMACHEM LIMITED - Analysis Report
Company Number: 13111184
Analysis Date: 2025-07-20 11:14 UTC
Risk Rating: HIGH
The company exhibits significant solvency risk, reflected by persistent negative net assets and shareholder funds, indicating liabilities substantially exceed assets. The dormant status and minimal capital further exacerbate concerns about operational viability and liquidity.Key Concerns:
- Consistent Negative Net Assets: Over the last three financial years, the company’s net assets remain deeply negative (£-62,545), signaling ongoing financial distress and potential insolvency risk.
- Dormant Status with Large Creditors: Although accounts classify the company as dormant, current liabilities stand at £62,645 with almost no assets, implying potential unpaid obligations and no active trading to cover these.
- Lack of Operational Activity: No employees and dormant filing status suggest no ongoing business operations, raising questions about future revenue generation and sustainability.
- Positive Indicators:
- Compliance with Filings: No overdue accounts or confirmation statements were noted, demonstrating adherence to regulatory filing deadlines which reduces governance risk.
- Stable Directorship: The company maintains two current directors with a stable appointment history since incorporation, which may indicate steady management oversight.
- Micro-Entity Accounting Exemptions: Utilization of micro-entity dormant exemptions reduces complexity and audit costs, appropriate given current inactivity.
- Due Diligence Notes:
- Investigate the nature and origin of the sizeable current liabilities and creditor claims given absence of trading activity.
- Verify the intentions of the shareholders and directors regarding future business plans or potential restructuring to address negative equity.
- Confirm no undisclosed contingent liabilities or off-balance-sheet risks exist despite dormant status.
- Review any related party transactions or loans that may have contributed to the financial position.
- Assess the impact of director resignations in 2021 and 2022 on corporate governance and continuity.
Sign in to generate a free AI analysis of this company — no password needed, just an email link.